KRAZATI® (adagrasib)
KRAZATI® (adagrasib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, …
Krazati: Uses, Dosage, Side Effects & Warnings - Drugs.com
Krazati is a targeted therapy for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) with an abnormal KRAS G12C gene. Krazati reduces tumor growth by locking the KRAS …
KRAZATI is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor …
Krazati (adagrasib，MRTX849，阿达格拉西布)中文说明书|香港济 …
KRAZATI是 RAS GTP酶家族 的抑制剂，用于治疗经FDA批准的检测确定的患有KRAS G12C突变，且既往至少接受过一次全身性治疗的局部晚期或转移性非小细胞肺癌 (NSCLC)的成年患者。
Adagrasib - Wikipedia
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. [1][2] Adagrasib is an inhibitor of G12C mutated KRAS GTPase. [1] It is …
KRAZATI（Adagrasib）美国获批上市，KRAS G12C患者的福音
2022年12月12日， Mirati Therapeutics 公司研发的 KRAZATI （Adagrasib）获得美国食品药品监督管理局（FDA）批准，用于治疗至少接受过一次系统治疗的KRAS. 突变的靶向药。 RAS基 …
KRAZATI® (adagrasib) | Information for Healthcare Providers
KRAZATI ® (adagrasib), as a single-agent, is indicated for the treatment of adult patients with KRAS G12C- mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) as …
Krazati（adagrasib）中文说明书-价格-适应症-不良反应及注意事 …
2024年4月9日 · 2022年12月12日，Mirati Therapeutics宣布FDA已加速批准Krazati（adagrasib），作为具有KRAS G12C突变的局部晚期或转移性非小细胞肺 …
Krazati - European Medicines Agency (EMA)
2023年7月21日 · Krazati is a medicine for treating adults with advanced non-small cell lung cancer (NSCLC) when the cancer cells have a particular genetic change (mutation) known as …
KRAZATI, as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by …